Legislator Rechtsprechung & Gesetzgebung
832.102 KVVOAMAL CH

Art. 65b Verordnung vom 27. Juni 1995 über die Krankenversicherung (KVV) - Beurteilung der Wirtschaftlichkeit: Grundsatz

KVV; 1. Teil: Obligatorische Krankenpflegeversicherung; 4. Titel: Leistungserbringer; 3. Kapitel: Tarife und Preise
Originalquelle öffnen Gesamter Erlass (261 Artikel) Maschinenlesbares Markdown (.md)

Art. 65b KVV · Beurteilung der Wirtschaftlichkeit: Grundsatz

Ein Arzneimittel gilt als wirtschaftlich, wenn es die indizierte Heilwirkung mit möglichst geringem finanziellem Aufwand gewährleistet.

Die Wirtschaftlichkeit eines Arzneimittels wird wie folgt beurteilt: a. anhand eines Vergleichs mit dem durchschnittlichen Preis anderer Arzneimittel zur Behandlung derselben Krankheit (therapeutischer Quervergleich); b. anhand eines Vergleichs mit dem Durchschnitt der Preise desselben Arzneimittels in den Referenzländern (Auslandpreisvergleich).

Zur Ermittlung des Preises, der als wirtschaftlich gilt, werden die nach Absatz 2 Buchstaben a und b ermittelten Preise je hälftig gewichtet.

← Art. 65a KVV Verordnung vom 27. Juni 1995 über die Krankenversicherung (KVV) - Versicherungspflicht Art. 65bbis KVV →

Fragen Sie sich, wie diese Gesetzesbestimmung auf Ihren Fall anwendbar ist?

Prüfen Sie diesen Erlass zusammen mit Rechtsprechung, Kommentaren und verwandten Gesetzesbestimmungen in Legislator AI.

Fall in Legislator öffnen →

Gerichtsentscheide zu dieser Bestimmung (102)

BGE 152 V 184 (Art. 64a, 65b, 65c, 65d, 65e KVV)
Therapeutic cross-comparison for multi-indication drug price review: combination product with added antibacterial main indication not a valid comparator to single-agent product.
Provisions governing the three-yearly review and the therapeutic cross-comparison, applied to the final price determination.
C-2996/2023 (Art. 65b Abs. 6 KVV)
Descovy Pricing Dispute: Court Affirms FOPH Price Reduction
This provision is cited as the basis for considering whether a successor drug without therapeutic progress should be treated differently in price comparisons, which was a central point of contention.
C-326/2022 (Art. 65b Abs. 4bis Bst. b KVV)
Drug Pricing: Average Dosage and Packaging Size for Comparison
Establishes that the cost of the medicine per day or per course is compared to the cost of medicines used for treating the same disease.
C-239/2022 (Art. 65b Abs. 1 KVV)
Patented Drug Price Protection Amidst TQV Error
Cited in the reasoning regarding the definition of a medicinal product being cost-effective.
C-239/2022 (Art. 65b Abs. 2 Bst. b KVV)
Patented Drug Price Protection Amidst TQV Error
Cited in the reasoning regarding the therapeutic cross-comparison (TQV) as a method to assess cost-effectiveness.
C-239/2022 (Art. 65b Abs. 4bis Bst. a KVV)
Patented Drug Price Protection Amidst TQV Error
Cited in the reasoning regarding the evaluation of effectiveness in relation to other medicines used for the same illness within the TQV.
C-239/2022 (Art. 65b Abs. 4bis Bst. b KVV)
Patented Drug Price Protection Amidst TQV Error
Cited in the reasoning regarding the evaluation of the cost of the medicinal product per day or course in relation to the costs of medicines used for the same illness within the TQV.
C-4935/2021 (Art. 65b Abs. 2 Bst. a KVV)
Pharmaceutical Price Increase Dispute
This provision, along with others, defines the economic viability of a medicinal product, which is the basis for determining the price.
C-424/2020 (Art. 65b Abs. 2 Bst. a KVV)
Federal Office of Public Health v. Drug Manufacturer (Price Reduction)
Cited as a basis for the principle that the foreign price comparison (APV) compares the same medicinal product.
C-424/2020 (Art. 65b Abs. 4bis Bst. b KVV)
Federal Office of Public Health v. Drug Manufacturer (Price Reduction)
Cited for the TQV principle of comparing costs per day or treatment duration.
C-2386/2021 (Art. 65b Abs. 4bis KVV)
Pharmaceutical Price Reduction Upheld in Swiss Health Insurance Case
Cited as the basis for the therapeutic cross-comparison (TQV) procedure.
C-2586/2021 (Art. 65b Abs. 1 KVV)
Federal Office of Public Health v. Medication Price and Indication Limitation
Cited for the definition of cost-effectiveness for a medicine, meaning it ensures the indicated therapeutic effect with minimal financial expenditure.
C-2586/2021 (Art. 65b Abs. 2 Bst. b KVV)
Federal Office of Public Health v. Medication Price and Indication Limitation
Cited for the method of assessing cost-effectiveness through therapeutic cross-comparison (TQV) with other medicines.
C-2586/2021 (Art. 65b Abs. 4bis KVV)
Federal Office of Public Health v. Medication Price and Indication Limitation
Cited for the scope of the therapeutic cross-comparison (TQV), focusing on efficacy and costs of medicines used for the same disease.
C-4596/2020 (Art. 65b Abs. 4bis Bst. a und b KVV)
Federal Administrative Court Annuls FOPH Price Reduction Decision Due to Flawed Therapeutic Comparison
The court determined that the therapeutic cross-comparison was not conducted correctly, impacting the legality of the decision.